Hematology and Oncology Book

http://www.fpnotebook.com/

Small Molecule Inhibitor-Mediated Chemotherapy

Advertisement

  1. Mechanism
    1. Targeted to Tyrosine Kinases, interfering with EGFR, HER2-neu and VEGF
    2. Small molecules that principally act intracellularly
    3. Less specific than monoclonal antibodies
  2. Pharmacokinetics
    1. Oral agents
    2. Very short half life (hours)
  3. Advantages
    1. Much less expensive than monoclonal antibodies
  4. Drug Interactions
    1. Multiple related to Cytochrome P450 enzymes
  5. Agents
    1. Bortezomib (Velcade)
    2. Dasatinib (Sprycel)
    3. Erlotinib (Tarceva)
    4. Gefitinib (Iressa)
    5. Imatinib (Gleevec)
    6. Lapatinib (Tykerb)
    7. Sorafenib (Nexavar)
    8. Sunitinib (Sutent)
  6. References
    1. Imai (2006) Nat Rev Cancer 6:714

Navigation Tree